Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
ALTEOGEN will participate in the ‘J.P. Morgan Healthcare Conference 2026’ in San Francisco, USA, to present its bio-platform technology and pipeline status/plans to major overseas institutional investors.
📊 [Key Disclosure Details & Major Figures Summary]
- Event Name: Participation in J.P. Morgan 2026 Healthcare Conference
- Date & Time: January 15, 2026, 11:30 – 12:00 (PST)
- Location: San Francisco, USA
- Target Audience: Major overseas institutional investors
- Purpose: To enhance investor understanding regarding corporate presentation and key business status
- Method:
- APAC Track Presentation (Jan 15, 11:30 am PST)
- 1-on-1 or group meetings with overseas institutional investors
- Key Details: ALTEOGEN’s bio-platform technologies, pipeline status, and future plans
- Sponsoring Institution: J.P. Morgan
- Confirmation Date: January 08, 2026
- Contact Department: IR Team (Tel: +82-42-384-8777)
- IR Material Publication: Scheduled for publication on January 15, 2026, on the KRX KIND system website (http://kind.krx.co.kr) and the company website (www.alteogen.com)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Bio-Platform Technology and Pipeline Updates via Published IR Materials
The company plans to publish its IR presentation materials on the KRX KIND system and its official website on January 15, 2026, for this event. Reviewing the official presentation materials provided to major global institutional investors is essential because it allows investors to accurately understand the progress of the company’s bio-platform technologies and pipeline strategic directions. Detailed contents can be cross-checked in the official IR presentation materials published on the KRX KIND system website and company website.
📢 Disclaimer & Source Notice
Source: This content has been structured and newly created based on official filing data from the Financial Supervisory Service (DART).
Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
